Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVANTHIA GALANIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1326028234
CMS profile
286517
Location
ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,425.00

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $1,925.00 1
Consulting Fee $500.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Agios Pharmaceuticals, Inc. $1,925.00 1
AstraZeneca Pharmaceuticals LP $500.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVANTHIA GALANIS

NPI 1326028234 · CMS profile ID 286517

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326028234?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326028234?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326028234?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1326028234?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $2,425.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Agios Pharmaceuticals, Inc. $1,925.0010/07/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751963903 CMS
AstraZeneca Pharmaceuticals LP $500.0003/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736328853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,425.00 2
PY2024 $20,258.52 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,021,227.49 388
PY2024 Principal investigator $12,702,832.22 309
PY2023 Principal investigator $371,957.47 19
PY2022 Principal investigator $13,006.11 2
PY2021 Principal investigator $94,282.54 7
PY2020 Principal investigator $16,250.00 1
PY2019 Principal investigator $20,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

388 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $85,644.72 12/22/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL No dispute reported 06/30/2026 1228721281
Principal investigator 1 Servier BioInnovation $1,579.00 11/28/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971297
Principal investigator 1 Janssen Research & Development, LLC $161,501.41 11/24/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONC
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) forMetastaticProstateCancer, ASPIRE Trial No dispute reported 06/30/2026 1175302868
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $403,309.28 11/15/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas No dispute reported 06/30/2026 1235967387
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $40,798,260.00 11/05/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas No dispute reported 06/30/2026 1235967383
Principal investigator 1 SERVIER PHARMACEUTICALS LLC $4,079,826.00 11/05/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas No dispute reported 06/30/2026 1235967385
Principal investigator 1 PFIZER INC. $572,700.00 10/13/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL No dispute reported 06/30/2026 1228814041
Principal investigator 1 PFIZER INC. $572,700.00 10/13/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
WI208323 PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN A CONJUGATED ANTICD22 MONOCLONAL ANTIBODY TO FRONTLINE THERAPY IN YOUNG ADULTS AGES 1639 YEARS WITH NEWLY DIAGNOSED PRECURSOR BCELL ALL No dispute reported 06/30/2026 1228814046
Principal investigator 1 AstraZeneca Pharmaceuticals LP $576,486.81 10/11/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer No dispute reported 06/30/2026 1185537345
Principal investigator 1 Servier BioInnovation $1,579.00 10/02/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971293
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379550
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379552
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379554
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379556
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379558
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379560
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379562
Principal investigator 1 Exelixis Inc. $108.00 09/30/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379564
Principal investigator 1 Janssen Research & Development, LLC $3,760.52 09/29/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377015
Principal investigator 1 Janssen Research & Development, LLC $552.49 09/29/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377023
Principal investigator 1 Janssen Research & Development, LLC $3,533.69 09/29/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377095
Principal investigator 1 Servier BioInnovation $5,500.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971249
Principal investigator 1 Servier BioInnovation $1,500.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971252
Principal investigator 1 Servier BioInnovation $450.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971257
Principal investigator 1 Servier BioInnovation $1,250.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971261
Principal investigator 1 Servier BioInnovation $586.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971265
Principal investigator 1 Servier BioInnovation $250.00 09/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971269
Principal investigator 1 Servier BioInnovation $1,579.00 09/03/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971240
Principal investigator 1 Servier BioInnovation $2,003.00 09/03/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971245
Principal investigator 1 PFIZER INC. $161,993.33 08/25/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228840493
Principal investigator 1 Servier BioInnovation $1,875.00 08/22/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971289
Principal investigator 1 AstraZeneca Pharmaceuticals LP $429,466.00 08/21/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer No dispute reported 06/30/2026 1185537343
Principal investigator 1 PFIZER INC. $161,993.33 08/18/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228840512
Principal investigator 1 PFIZER INC. $50,944.32 08/11/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228834440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.75 07/29/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION
A RANDOMIZED PHASE II TRIAL WITH A SAFETY LEAD IN TO EVALUATE PALBOCICIB VS PALBOCICIB CEMIPLIMAB FOR THE TREATMENT OF ADVANCED DEDIFFERENTIATED LIPOSARCOMA No dispute reported 06/30/2026 1184221352
Principal investigator 1 Servier BioInnovation $1,579.00 07/29/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971281
Principal investigator 1 PFIZER INC. $161,993.33 07/14/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228842067
Principal investigator 1 Servier BioInnovation $1,500.00 07/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971273
Principal investigator 1 Servier BioInnovation $1,250.00 07/11/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971278
Principal investigator 1 Servier BioInnovation $2,003.00 06/27/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971233
Principal investigator 1 PFIZER INC. $9,511.47 06/16/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228845168
Principal investigator 1 Servier BioInnovation $1,579.00 06/16/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971228
Principal investigator 1 Servier BioInnovation $1,579.00 06/16/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971236
Principal investigator 1 Genentech, Inc. $39,366.60 05/29/2025 Non-covered Recipient Entity
ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
AFT57 Induction and adjuvant atezolizumab with or without tiragolumab in stage III NSCLC Randomize No dispute reported 06/30/2026 1211571718
Principal investigator 1 Novartis Pharmaceuticals Corporation $746,740.00 05/15/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING NASSAU
RANDOMIZED PHASE II STUDY OF SORAFENIB and or EVEROLIMUS IN PATIENTS WITH RADIOACTIVE IODINE REFRACTORY HuRTHLE CELL THYROID CANCER No dispute reported 06/30/2026 1190310104
Principal investigator 1 Janssen Research & Development, LLC $576,321.37 05/12/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377060
Principal investigator 1 PFIZER INC. $9,511.47 05/12/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228856296
Principal investigator 1 PFIZER INC. $161,993.33 05/05/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228851420
Principal investigator 1 PFIZER INC. $9,511.47 04/29/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228854991
Principal investigator 1 Genentech, Inc. $255,758.02 04/28/2025 Non-covered Recipient Entity
ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
A PHASE IB II UMBRELLA STUDY OF TARGETED AGENTS WITH ATEZOLIZUMAB FOR PATIENTS WITH RECURRENT OR PER No dispute reported 06/30/2026 1211571711
Principal investigator 1 PFIZER INC. $194,866.00 04/18/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1228850467
Principal investigator 1 Janssen Research & Development, LLC $5,350.33 04/14/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377029
Principal investigator 1 Janssen Research & Development, LLC $6,471.95 04/14/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377069
Principal investigator 1 Janssen Research & Development, LLC $17,807.49 04/14/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma No dispute reported 06/30/2026 1175377076
Principal investigator 1 PFIZER INC. $161,993.33 04/14/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228854999
Principal investigator 1 PFIZER INC. $4,295,583.47 03/31/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855039
Principal investigator 1 Servier BioInnovation $2,003.00 03/31/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971224
Principal investigator 1 Servier BioInnovation $1,579.00 03/14/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971215
Principal investigator 1 Servier BioInnovation $1,579.00 03/14/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,688.55 03/05/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION
ALLIANCE A061202 A PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND MLN9708 VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE AND PROTEASOME INHIBITOR-BASED THERAPY No dispute reported 06/30/2026 1235957764
Principal investigator 1 PFIZER INC. $50,944.32 02/10/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855031
Principal investigator 1 Genentech, Inc. $1,024,222.03 02/07/2025 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
FOLFOX Alone or Combined with a PD L1 No dispute reported 06/30/2026 1211571726
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378922
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378924
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378926
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378928
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378930
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378932
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378934
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378936
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378938
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378940
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378942
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378944
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378946
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378948
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378950
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378952
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378954
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378956
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378958
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378960
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378962
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378964
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378966
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378968
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378970
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378972
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378974
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378976
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378978
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378980
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378982
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378984
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378986
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378988
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378990
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378992
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378994
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378996
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222378998
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379000
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379002
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379004
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379006
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379008
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379010
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379012
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379014
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379016
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379018
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379020
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379022
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379024
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379026
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379028
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379030
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379032
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379034
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379036
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379038
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379040
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379042
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379044
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379046
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379048
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379050
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379052
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379054
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379056
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379058
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379060
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379062
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379064
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379066
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379068
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379070
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379072
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379074
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379076
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379078
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379080
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379082
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379084
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379086
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379088
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379090
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379092
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379094
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379096
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379098
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379100
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379102
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379104
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379106
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379108
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379110
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379112
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379114
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379116
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379118
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379120
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379122
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379124
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379126
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379128
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379130
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379132
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379134
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379136
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379138
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379140
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379142
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379144
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379146
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379148
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379150
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379152
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379154
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379156
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379158
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379160
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379162
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379164
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379166
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379168
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379170
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379172
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379174
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379176
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379178
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379180
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379182
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379184
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379186
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379188
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379190
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379192
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379194
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379196
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379198
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379200
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379202
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379204
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379206
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379208
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379210
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379212
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379214
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379216
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379218
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379220
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379222
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379224
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379226
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379228
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379230
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379232
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379234
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379236
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379238
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379240
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379242
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379244
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379246
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379248
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379250
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379252
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379254
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379256
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379258
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379260
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379262
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379264
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379266
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379268
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379270
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379272
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379274
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379276
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379278
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379280
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379282
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379284
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379286
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379288
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379290
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379292
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379294
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379296
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379298
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379300
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379302
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379304
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379306
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379308
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379310
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379312
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma No dispute reported 06/30/2026 1222379314
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379316
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379318
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379320
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379322
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379324
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379326
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379328
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379330
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379332
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379334
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379336
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379338
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379340
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379342
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379344
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379346
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379348
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379350
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379352
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379354
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379356
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379358
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379360
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379362
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379364
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379366
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379368
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379370
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379372
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379374
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379376
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379378
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379380
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379382
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379384
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379386
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379388
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379390
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379392
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379394
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379396
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379398
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379400
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379402
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379404
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379406
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379408
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379410
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379412
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379414
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379416
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379418
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379420
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379422
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379424
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379426
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379428
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379430
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379432
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379434
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379436
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379438
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379440
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379442
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379444
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379446
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379448
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379450
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379452
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379454
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379456
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379458
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379460
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379462
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379464
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379466
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379468
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379470
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379472
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379474
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379476
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379478
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379480
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379482
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379484
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379486
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379488
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379490
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379492
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379494
Principal investigator 1 Exelixis Inc. $108.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) No dispute reported 06/30/2026 1222379496
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379498
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379500
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379502
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379504
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379506
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379508
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379510
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379512
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379514
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379516
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379518
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379520
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379522
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379524
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379526
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379528
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379530
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379532
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379534
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379536
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379538
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379540
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379542
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379544
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379546
Principal investigator 1 Exelixis Inc. $500.00 02/03/2025 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1222379548
Principal investigator 1 Genentech, Inc. $1,911.00 01/30/2025 Non-covered Recipient Entity
ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
AFT57 Induction and adjuvant atezolizumab with or without tiragolumab in stage III NSCLC Randomize No dispute reported 06/30/2026 1211571714
Principal investigator 1 Servier BioInnovation $1,579.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971157
Principal investigator 1 Servier BioInnovation $1,579.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971162
Principal investigator 1 Servier BioInnovation $2,003.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971166
Principal investigator 1 Servier BioInnovation $1,579.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971183
Principal investigator 1 Servier BioInnovation $1,579.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971195
Principal investigator 1 Servier BioInnovation $2,003.00 01/17/2025 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1235971207
Principal investigator 1 PFIZER INC. $2,162,820.08 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228855007
Principal investigator 1 PFIZER INC. $161,993.33 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228860723
Principal investigator 1 PFIZER INC. $161,993.33 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228860731
Principal investigator 1 PFIZER INC. $161,993.33 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228860737
Principal investigator 1 Novartis Pharmaceuticals Corporation $370,087.24 01/07/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
RANDOMIZED PHASE II STUDY OF SORAFENIB and or EVEROLIMUS IN PATIENTS WITH RADIOACTIVE IODINE REFRACTORY HuRTHLE CELL THYROID CANCER No dispute reported 06/30/2026 1190313455